Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 14/20 | 0.67 |
| ▸ | CKS1B | P61024 | 3/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30925420 | 1.00 | SLC40A1 (0.67) | SLC40A1CKS1BSKP2GLO1MMP2 | |
| SCHEMBL11973205 | 0.81 | SLC40A1 (1.00) | SLC40A1CKS1BSKP2GLO1MMP2 | |
| SCHEMBL11995656 | 0.78 | SLC40A1 (1.00) | SLC40A1GLO1 | |
| SCHEMBL11973789 | 0.75 | SLC40A1 (0.71) | SLC40A1CKS1BSKP2MEN1KMT2A | |
| SCHEMBL11995655 | 0.73 | SLC40A1 (1.00) | SLC40A1CKS1BSKP2MEN1KMT2A | |
| SCHEMBL26964471 | 0.72 | SLC40A1 (0.70) | SLC40A1 | |
| SCHEMBL29800726 | 0.72 | SLC40A1 (0.70) | SLC40A1 | |
| SCHEMBL11973381 | 0.72 | SLC40A1 (0.65) | SLC40A1MEN1KMT2ATDP1 | |
| SCHEMBL27214226 | 0.69 | SLC40A1 (0.62) | SLC40A1CKS1BSKP2GLO1MMP2 | |
| SCHEMBL30925523 | 0.69 | SLC40A1 (0.59) | SLC40A1CKS1BSKP2GLO1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | SLC40A1 3357/4885CKS1B 2287/4885SKP2 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.